{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-23-000005","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.669517+00:00","generated_at":"2026-06-20T17:49:59.850465+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Guardant Health prelim FY22 revenue $447-450M, up 20%; test volumes up >40% YoY","bullets":["Preliminary FY22 revenue $447M-$450M, up 20% YoY; Q4 revenue $124M-$127M, up 15-17%.","FY22 clinical test volumes 124,800 (+42% YoY); biopharma tests 26,000 (+40% YoY).","Q4 clinical tests 36,000 (+41% YoY); biopharma tests 8,200 (+24% YoY).","Cash, equivalents and marketable debt securities $1.0B as of Dec 31, 2022.","Positive ECLIPSE trial readout for Shield blood-based colorectal cancer test; expanding to lung cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-23-000005","json":"https://secwatch.observer/filing/0001576280-23-000005.json","markdown":"https://secwatch.observer/filing/0001576280-23-000005.md","text":"https://secwatch.observer/filing/0001576280-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/0001576280-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/gh-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:49:59.850465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4edce1691c32beb54931c701af4339fb8b8f21dd","claim":"Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue between $447 million and $450 million.","evidence_excerpt":"Full year 2022 preliminary unaudited financial results For the twelve-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $447 million and $450 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/0001576280-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"between $447 million and $450 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"eca379afb8205b4d03ca2996d1dd0496b3dd2e48","claim":"Guardant Health, Inc. reported the quarter ended December 31, 2022 results: revenue between $124 million and $127 million.","evidence_excerpt":"Fourth quarter 2022 preliminary unaudited financial results For the three-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $124 million and $127 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/0001576280-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"between $124 million and $127 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}